De-escalating Surgery Among Patients with HER2+and Triple Negative Breast Cancer

被引：2

作者：

Tasoulis, Marios-Konstantinos ^{[1
,2
]}

Heil, Joerg ^{[3
]}

Kuerer, Henry M. ^{[4
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Breast Surg Unit, Fulham Rd, London SW3 6JJ, England

[2] Inst Canc Res, Div Breast Canc Res, Old Brompton Rd, London SW7 3RP, England

[3] Heidelberg Univ Hosp, Univ Breast Unit, Dept Obstet & Gynecol, Heidelberg, Germany

[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA

来源：

CURRENT BREAST CANCER REPORTS | 2022年 / 14卷 / 04期

关键词：

Surgical de-escalation; Breast surgery; Triple negative; HER2; positive; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; SENTINEL NODE BIOPSY; 20-YEAR FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY; RADICAL-MASTECTOMY; MULTICENTER; TRIAL; IDENTIFICATION; AXILLA; IMPACT;

D O I：

10.1007/s12609-022-00453-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions. Recent Findings Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery. Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders.

引用

页码：135 / 141

页数：7

共 50 条

[1] De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
Marios-Konstantinos Tasoulis
Joerg Heil
Henry M. Kuerer
Current Breast Cancer Reports, 2022, 14 : 135 - 141
[2] De-escalating and escalating treatment in patients with triple negative breast cancer
Carey, L.
BREAST, 2017, 32 : S21 - S21
[3] De-escalating and escalating systemic therapy in triple negative breast cancer
Carey, Lisa A.
BREAST, 2017, 34 : S112 - S115
[4] De-escalating and escalating treatment in patients with HER2 positive breast cancer
Joensuu, H.
BREAST, 2017, 32 : S20 - S21
[5] De-escalating and escalating surgery in the management of early breast cancer
Morrow, Monica
BREAST, 2017, 34 : S1 - S4
[6] De-escalating and escalating surgery in the management of early breast cancer
Morrow, M.
BREAST, 2017, 32 : S2 - S2
[7] Escalating and de-escalating treatment in HER2-positive early breast cancer
Joensuu, Heikki
CANCER TREATMENT REVIEWS, 2017, 52 : 1 - 11
[8] De-escalating treatment with neoadjuvant chemotherapy in early triple-negative breast cancer
Murillo, Serafin Morales
Cudos, Ariadna Gasol
Der-Abrain, Noemi Tuset
CANCER RESEARCH, 2024, 84 (09)
[9] De-escalating systemic chemotherapy might be considered for pure triple negative apocrine breast cancer patients
Altundag, Kadri
JOURNAL OF BUON, 2019, 24 (02): : 864 - 864
[10] De-escalating systemic therapy in triple negative breast cancer: The example of secretory carcinoma
Benabu, J-C
Stoll, F.
Koch, A.
Moliere, S.
Bellocq, J-P
Mathelin, C.
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2018, 47 (04) : 163 - 165

← 1 2 3 4 5 →